Jon K. Hayashida - 10 May 2021 Form 4 Insider Report for STAAR SURGICAL CO (STAA)

Role: VP, Global Clinical, Medical
Signature: /s/ Samuel Gesten as attorney-in-fact for Dr. Jon Hayashida
Issuer symbol: STAA
Transactions as of: 10 May 2021
Net transactions value: -$1,036,156
Form type: 4
Filing time: 12 May 2021, 17:05:20 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	STAA	Common Stock	Sale	$168,922	-1,349	-14%	$125.22	8,342	10 May 2021	Direct	F1
transaction	STAA	Common Stock	Options Exercise	$116,280	+7,200	+86%	$16.15	15,542	10 May 2021	Direct
transaction	STAA	Common Stock	Options Exercise	$75,513	+2,534	+16%	$29.80	18,076	10 May 2021	Direct
transaction	STAA	Common Stock	Options Exercise	$124,563	+3,462	+19%	$35.98	21,538	10 May 2021	Direct
transaction	STAA	Common Stock	Options Exercise	$152,048	+5,523	+26%	$27.53	27,061	10 May 2021	Direct
transaction	STAA	Common Stock	Sale	$1,335,639	-10,760	-40%	$124.13	16,301	10 May 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	STAA	Common Stock Options	Options Exercise	$0	-7,200	-100%	$0.000000^*	0	10 May 2021	Common Stock	7,200	$16.15	Direct	F3
transaction	STAA	Common Stock Options	Options Exercise	$0	-2,534	-77%	$0.000000	750	10 May 2021	Common Stock	2,534	$29.80	Direct	F4
transaction	STAA	Common Stock Options	Options Exercise	$0	-3,462	-29%	$0.000000	8,564	10 May 2021	Common Stock	3,462	$35.98	Direct	F5
transaction	STAA	Common Stock Options	Options Exercise	$0	-5,523	-36%	$0.000000	9,774	10 May 2021	Common Stock	5,523	$27.53	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.02 to $135.64, inclusive.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.85 to $135.64, inclusive.
F3	The options granted become exercisable as follows: 1/3 on 3/15/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/15/2028.
F4	The options granted become exercisable as follows: 1/3 on 6/14/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 6/14/2028.
F5	The options granted become exercisable as follows: 1/3 on 3/14/2020 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/14/2022.
F6	The options granted become exercisable as follows: 1/3 on 3/20/2021 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/20/2023.